Helogen raises $7.1M seed to build space factories for medical implants

What's the deal? HelogenDealroom has a profile for this one. Try Dealroom →, a New York-based space biotechnology and in-orbit manufacturing startup, has raised $7.1 million in seed funding. The round was co-led by RRE Ventures and OceansDealroom has a profile for this one. Try Dealroom →, with participation from One Way VenturesDealroom has a profile for this one. Try Dealroom → and BlisceDealroom has a profile for this one. Try Dealroom →.

What's the endgame? Led by chief executive officer Shishir Bankapur, Helogen builds automated laboratory hardware and robotic equipment to operate in microgravity. Its remote-controlled bioreactors and crystallization chambers sit inside orbiting satellite modules, using the weightless environment to synthesize advanced biomaterials for medical implants.

How it works: The cloud-linked system manages real-time environmental telemetry to automate cell cultivation and material synthesis. Helogen says this lets biopharma companies and academic teams design implants with near-perfect molecular structures and purity that are impossible to replicate in labs on Earth.

Where the money goes: Helogen will fund the mechanical scaling of its fabrication hardware, expand its aerospace engineering and molecular biology teams, and accelerate customer-funded biological research programs.

The signal: At $7.1 million, Helogen's seed sits in the top 5% of all US nanotech seed rounds on record — a sign of investor appetite for the emerging intersection of space infrastructure and biotech, where microgravity manufacturing promises materials terrestrial labs cannot match.

Image credit: Helogen